These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30690754)

  • 21. Prognostic indicators of survival in sinonasal extranodal natural killer/T-cell lymphoma.
    Varelas AN; Ganti A; Eggerstedt M; Tajudeen BA
    Laryngoscope; 2019 Dec; 129(12):2675-2680. PubMed ID: 30801751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD30-positive cutaneous extranodal natural killer/T-cell lymphoma: clinicopathological features and survival outcomes.
    Lee WJ; Moon IJ; Shin HJ; Won CH; Chang SE; Choi JH; Lee MW
    Int J Dermatol; 2019 Jun; 58(6):688-696. PubMed ID: 30597548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunophenotypic and clinical differences between the nasal and extranasal subtypes of upper aerodigestive tract natural killer/T-cell lymphoma.
    Liu QF; Wang WH; Wang SL; Liu YP; Huang WT; Lu N; Zhou LQ; Ouyang H; Jin J; Li YX
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):806-13. PubMed ID: 24495590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical features and survival of extranodal natural killer/T cell lymphoma with and without hemophagocytic syndrome.
    Jia J; Song Y; Lin N; Liu W; Ping L; Zheng W; Wang X; Xie Y; Tu M; Zhang C; Ying Z; Deng L; Ding N; Zhu J
    Ann Hematol; 2016 Dec; 95(12):2023-2031. PubMed ID: 27595760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nasal-type extranodal T-cell/NK lymphoma in association with hemophagocytic syndrome.
    Guedes JCR; Cunha KAPFD; Machado JRDS; Pinto LW
    An Bras Dermatol; 2018 Jun; 93(3):422-425. PubMed ID: 29924244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type.
    Liu X; Wang B; Ma X; Guo Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):418-24. PubMed ID: 19395464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma.
    Wang H; Li YX; Wang WH; Jin J; Dai JR; Wang SL; Liu YP; Song YW; Wang ZY; Liu QF; Fang H; Qi SN; Liu XF; Yu ZH
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1115-21. PubMed ID: 21514070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A clinical study of 115 patients with extranodal natural killer/T-cell lymphoma, nasal type.
    Wu X; Li P; Zhao J; Yang X; Wang F; Yang YQ; Fang F; Xu Y; Zhang H; Wang WY; Yi C
    Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):619-25. PubMed ID: 18790372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerance of pegaspargase-based chemotherapy in patients with nasal-type extranodal NK/T-cell lymphoma: a pilot study.
    Wen JY; Li M; Li X; Chen J; Lin Q; Ma XK; Dong M; Wei L; Chen ZH; Wu XY
    Asian Pac J Cancer Prev; 2014; 15(15):6275-81. PubMed ID: 25124611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma.
    Kim HS; Kim KH; Kim KH; Chang MH; Ji SH; Lim DH; Kim K; Kim SJ; Ko Y; Ki CS; Jo SJ; Lee JW; Kim WS
    Leuk Lymphoma; 2009 May; 50(5):757-63. PubMed ID: 19330658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
    Yamaguchi M; Tobinai K; Oguchi M; Ishizuka N; Kobayashi Y; Isobe Y; Ishizawa K; Maseki N; Itoh K; Usui N; Wasada I; Kinoshita T; Ohshima K; Matsuno Y; Terauchi T; Nawano S; Ishikura S; Kagami Y; Hotta T; Oshimi K
    J Clin Oncol; 2009 Nov; 27(33):5594-600. PubMed ID: 19805668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The factors associated with the early diagnosis of nasal NK/T-cell lymphoma with prominent ocular symptoms and general nasal NKTL.
    Hu ZZ; Wang Y
    Am J Otolaryngol; 2019; 40(3):353-357. PubMed ID: 30717991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of standardized uptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: A multicenter, retrospective analysis.
    Pak K; Kim BS; Kim K; Kim IJ; Jun S; Jeong YJ; Shim HK; Kim SD; Cho KS
    Am J Otolaryngol; 2018; 39(1):1-5. PubMed ID: 29056243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathologic and molecular features of 122 Brazilian cases of nodal and extranodal NK/T-cell lymphoma, nasal type, with EBV subtyping analysis.
    Gualco G; Domeny-Duarte P; Chioato L; Barber G; Natkunam Y; Bacchi CE
    Am J Surg Pathol; 2011 Aug; 35(8):1195-203. PubMed ID: 21716086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
    Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
    Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
    Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
    EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extranodal natural killer/T-Cell lymphoma: A population-based comparison of sinonasal and extranasal disease.
    Vazquez A; Khan MN; Blake DM; Sanghvi S; Baredes S; Eloy JA
    Laryngoscope; 2014 Apr; 124(4):888-95. PubMed ID: 24114591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
    Kim SJ; Kim K; Kim BS; Kim CY; Suh C; Huh J; Lee SW; Kim JS; Cho J; Lee GW; Kang KM; Eom HS; Pyo HR; Ahn YC; Ko YH; Kim WS
    J Clin Oncol; 2009 Dec; 27(35):6027-32. PubMed ID: 19884539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beclin 1 expression: a predictor of prognosis in patients with extranodal natural killer T-cell lymphoma, nasal type.
    Huang JJ; Li HR; Huang Y; Jiang WQ; Xu RH; Huang HQ; Lv Y; Xia ZJ; Zhu XF; Lin TY; Li ZM
    Autophagy; 2010 Aug; 6(6):777-83. PubMed ID: 20639699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type.
    Wang L; Wang H; Li PF; Lu Y; Xia ZJ; Huang HQ; Zhang YJ
    Ann Hematol; 2015 Aug; 94(8):1381-8. PubMed ID: 25865943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.